Please login to the form below

Not currently logged in
Email:
Password:

Dendreon CEO to step down

John Johnson to leave next summer as Provenge sales stall

Dendreon has announced that CEO John Johnson will leave the company in August next year.

The decision comes as Dendreon continues to struggle as its only product Provenge – a 'vaccine' for prostate cancer ' – fails to live up to high expectations.

According to the company's financial report, sales of Provenge declined from $325m in 2012 to $286m in 2013. This led to Dendreon dropping out the top 25 companies working in oncology.

These poor sales meant the company reported operating losses of around $300m and major job cuts.

On leaving, Johnston said: "I first joined Dendreon because of my admiration for the company as a pioneer in immunotherapy and because of my belief in the power of Provenge as a personalised cancer treatment. That belief still holds true today.”

11th June 2014

Share

Subscribe to our email news alerts

PMHub

Add my company
Springer Nature

Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....